Nouscom, with one major partner and strong confidence, is building research and manufacturing foundations to address significant market needs with its neoantigen cancer vaccine platform. 

Private Company Edition: The €740m ($806.5m) Gilde Healthcare Venture&Growth VI Fund will back companies in Europe and North America. Among recent financings, VectorY raised a €129m ($138m) series A round, EyeBio expanded its series A to $130m and MBrace raised an $85m series B.

Oncology division officials summarize the agreements and discussions reached during formal meetings so there are no misunderstandings later. Sponsors want the practice used more widely by the FDA.

From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.